BIO Asia–Taiwan 2025 亞洲生技大會

4 July, 2023
BIO Asia–Taiwan 2023, an international gathering jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO); will be held from July 26th to 30th at the Taipei Nangang Exhibition Center, Hall 1 (TaiNEX 1). At this year’s exhibition, a total of 750 companies and organizations will showcase their offerings, surpassing the scale of the event prior to the pandemic. In addition, there will be 23 international forums, with biotech professionals from more than 30 countries expected to attend.
 
With the theme for BIO Asia–Taiwan this year being "Embracing Asian Dynamics," the gathering will include the following: An international conference, a four-day exhibition, one-on-one partnering meetings, a full schedule of company presentations, and a series of themed seminars.
 
A highlight of the exhibition will be the CDMO (Contract Development and Manufacturing Organization) zone, first established last year and expanded for this year’s occasion. Both domestic and international CDMO providers, including EirGenix, Formosa Laboratories, Bora Pharmaceuticals, TCI, China Chemical & Pharmaceutical, Mycenax Biotech, TFBS Bioscience, Genomics, Adimmune, Genovior Biotech, Level Biotechnology, Dr Signal BioTechnology, Amaran Biotech, and Zillion Fine Chemicals, as well as international companies such as BD, FUJIFILM, and Wuxi Biologics, will participate, showcasing their latest technologies, equipment, and business strategies.
 
To demonstrate Taiwan's clinical trial capabilities, a CRO (Contract Research Organization) zone has been added this year, with the participation of well-known domestic and international clinical trials entities such as Efficient Pharma Management (EffPha), Amaris, and Mithra Biotechnology. Many global-renowned CRO companies including LabCorp and ThermoFisher will also participate for the first time this year.
 
After the lifting of pandemic-era international travel restrictions, BIO Asia–Taiwan 2023 will boast record-breaking levels of international participation. The exhibition will host exhibitors from 20 countries, while the USA, the UK, Australia, Switzerland, Belgium, Italy, Poland, India, Malaysia, and Austria will host their own national pavilions. Last year’s "Regional Collaboration Forum" has also expanded in scale this year, with Japan, Australia, Canada, Malaysia, India, Lithuania, and Hong Kong each hosting their own forums, leading their own delegations to Taiwan for this occasion. Over 40 companies are expected to participate, boosting international participation and promoting cooperation and fundraising opportunities for Taiwan's biomedical industries.
 
This year’s Conference will cover some of the industry’s hottest topics, such as 2024 international investment trends, innovative technologies such as mRNA and gene therapy, and market supply chains. The opening ceremony on the first day will feature speeches by three key scientists: Katalin Kariko, Drew Weissman, and Pieter Cullis, who are best known for successfully developed the mRNA vaccine for COVID-19, and who were awarded the Tang Prize for this critical achievement. Together they will share their journey to developing mRNA vaccines, and will cover the latest trends in therapeutical mRNA applications.
 
Investment and financial sessions will again be a feature of the conference, with a number of international investment banks and investors invited to discuss the latest financial trends. This includes renowned figures such as Peter Kurz aka ‘Mr. Taiwan’, Chief Strategy Officer, QIC International; Sam Thong, Managing Director, Goldman Sachs; Michael Brinkman, Managing Director, Joint US Head of Biopharmaceuticals Investment Banking, Jefferies; Makiko Iwai, Head of Healthcare IB, Citi Group; and David Chen, Deputy Director of Business Development at Nasdaq Greater China.
 
Other important speakers include John Murphy, Chief Policy Officer Deputy Counsel, Healthcare, Biotechnology Innovation Organization (BIO), who will discuss the Impact of Key Policy Changes on Biopharma Industry. Renowned international market research firm Frost & Sullivan, international pharmaceutical and information provider IQVIA, and international CRO firm Syneos Health will also share their perspectives on major future trends and prospects for the biomedical sector, including precision medicine and clinical trials. The CDMO (Contract Development and Manufacturing Organization) industry, which has gained recent global prominence due to the industry-disrupting effects of the pandemic, will also be covered in a discussion led by PwC Strategy&, sharing insights on the global supply chain and CDMO trends in the post-pandemic era.
 
The organizing committee of BIO Asia–Taiwan 2023 is excited to report that both the exhibition and conference have seen a significant boost in international interest and participation this year. They hope that BIO Asia–Taiwan 2023 will continue to promote and encourage international business exchange, and cooperation, and expand the international participation and synergy within all sectors of Taiwan's biomedical industry.
 
聯絡人：台灣生物產業發展協會 蔡幸陵Daisy | 0933-139647 | Line ID: daisy222